Compare · GLP-1 agonist
Liraglutide vs Tirzepatide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Liraglutide | Tirzepatide | |
|---|---|---|
| Evidence | Strong human | Strong human |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | A once-daily GLP-1 drug with large RCT support for glucose control, weight loss, and lower cardiovascular risk in high-risk type 2 diabetes. | A dual GIP/GLP-1 receptor agonist with strong RCT evidence for type 2 diabetes, weight loss, and sleep apnea; GI side effects are common. |
| Full profile → | Full profile → |
Liraglutide
Liraglutide is one of the better-studied metabolic drugs of the last fifteen years, and the direct predecessor to semaglutide. Its two approved uses rest on large, replicated, double-blind randomized trials with hard endpoints, so the honest job here is to separate what the evidence firmly supports…
Tirzepatide
Tirzepatide is a once-weekly injectable peptide sold as Mounjaro (for type 2 diabetes) and Zepbound (for weight management and sleep apnea). Unlike most compounds we cover here, it has been tested in large, well-run human trials, and the results are unusually consistent. This is not medical advice.